Bank of New York Mellon Corp Decreases Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

Bank of New York Mellon Corp cut its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 1.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 202,941 shares of the company’s stock after selling 2,737 shares during the period. Bank of New York Mellon Corp owned about 0.26% of Kura Oncology worth $1,768,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after buying an additional 1,750 shares during the period. Point72 DIFC Ltd acquired a new stake in shares of Kura Oncology in the third quarter worth $146,000. Erste Asset Management GmbH acquired a new stake in Kura Oncology during the third quarter valued at $215,000. Bellevue Group AG lifted its holdings in Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after purchasing an additional 3,600 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Kura Oncology during the third quarter valued at $268,000.

Kura Oncology Price Performance

NASDAQ:KURA opened at $7.84 on Friday. The firm has a market cap of $633.12 million, a price-to-earnings ratio of -3.32 and a beta of 0.85. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average is $7.82 and its two-hundred day moving average is $12.43. Kura Oncology, Inc. has a 12-month low of $6.79 and a 12-month high of $23.48.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million. Research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Buying and Selling

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

KURA has been the topic of several research reports. StockNews.com downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, March 18th. Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Finally, JMP Securities reissued a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a research note on Thursday, February 6th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.